Allyx Therapeutics Announces License For The Treatment of Cognitive Deficits in Neurodegenerative Disorders From Bristol Myers Squibb And Yale
Share Article
Allyx Therapeutics expects to advance ALX-001, an mGluR5 modulator for Alzheimer’s disease, into clinical trials in 2021 NEW HAVEN, Conn. (PRWEB) January 13, 2021 Today, Allyx Therapeutics announced the completion of a license agreement with Bristol Myers Squibb to develop Allyx’s novel therapy for Alzheimer’s disease. The agreement includes a sublicense of certain rights from Yale University. To protect vulnerable neurons and preserve cognition in Alzheimer’s patients, Allyx expects to advance ALX-001, a small-molecule modulator of metabotropic glutamate receptor 5 (mGluR5), licensed from Bristol Myers Squibb, into clinical trials in 2021.
For Immediate Release, December 22, 2020
Contact:
Steve Bloch, Southern Utah Wilderness Alliance, (801) 859-1552, steve@suwa.org
Anne Hawke, Natural Resources Defense Council, (646) 823-4518, ahawke@nrdc.org
Taylor McKinnon, Center for Biological Diversity, (801) 300-2424, tmckinnon@biologicaldiversity.org
John Weisheit, Living Rivers, (435) 260-2590, john@livingrivers.org
Court Blocks Drilling Set to Begin in Newly Designated Utah Wilderness
WASHINGTON A federal judge today enjoined the Trump administration’s approval of a plan to punch a helium well into the heart of the Labyrinth Canyon Wilderness in Utah just two days before Christmas. Road construction was set to begin Wednesday.
“Labyrinth Canyon Wilderness is too special to drill,” said Landon Newell, staff attorney with the Southern Utah Wilderness Alliance. “We’re grateful the court enjoined this ill-conceived project and gave this incomparable landscape a brief reprieve. We’ll
Liquidia Corporation Announces Chief Executive Officer Transition
Liquidia Corporation Announces Chief Executive Officer Transition
RESEARCH TRIANGLE PARK, N.C., Dec. 14, 2020 Liquidia Corporation (NASDAQ: LQDA) today announced Damian deGoa has been appointed as Chief Executive Officer (CEO) and a director of the Company, effective immediately. He succeeds Neal F. Fowler who has retired as CEO and a director of the Company. Mr. Fowler has agreed to provide assistance to the Company for a short period of time to support a smooth transition.
“Damian is a strategic and proven leader in the healthcare industry, having led several companies in various stages of operations, most notably as Chief Executive Officer of RareGen from its formation in Summer 2018 through its acquisition by Liquidia in November 2020,” said Dr. Stephen Bloch, Chairman of the Company’s Board of Directors. “We are thrilled to welcome Damian’s wealth of experience in the pulmonary arterial hypertensio
For Immediate Release, December 18, 2020
Contact:
Landon Newell, Southern Utah Wilderness Alliance, (801) 428-3991, landon@suwa.org Steve Bloch, Southern Utah Wilderness Alliance, (801) 859-1552, steve@suwa.org
Anne Hawke, Natural Resources Defense Council, (646) 823-4518, ahawke@nrdc.org
Taylor McKinnon, Center for Biological Diversity, (801) 300-2424, tmckinnon@biologicaldiversity.org
John Weisheit, Living Rivers, (435) 260-2590, john@livingrivers.org
Lawsuit Challenges Trump Administration Permitting for Helium Drilling in Newly Designated Utah Wilderness
WASHINGTON Conservation groups have sued the Bureau of Land Management to challenge its illegal leasing of 1,400 acres for helium extraction within the newly designated Labyrinth Canyon Wilderness in southeastern Utah. The Southern Utah Wilderness Alliance, Natural Resources Defense Council, Center for Biological Diversity and Living Rivers filed suit Monday in federal district court.